1月20日，国新办举行新闻发布会，邀请财政部副部长廖岷，以及财政部综合司司长李先忠、金融司司 长于红，介绍发挥积极财政政策作用，推动经济社会高质量发展有关情况，并答记者问。 三是强化企业科技创新主体地位。落实好结构性减税降费政策，重点支持科技创新和制造业发展。继续 发挥专精特新"小巨人"发展奖补政策，还有国家中小企业发展基金等政策作用，提升中小企业的创新能 力和专业化水平，助力培育更多专精特新企业、单项冠军企业、瞪羚企业和独角兽企业。 四是加快重大科技成果高效转化应用。落实首台（套）、首批次保险补偿政策，持续支持符合条件的科 技创新产品迭代更新和应用推广。 南方财经·21世纪经济报道记者现场提问：财税政策是支持科技创新的重要工具。2025年财政部采取了 一系列举措支持科技自立自强，请问成效如何？接下来在加快培育新动能方面，有哪些重点安排？ 财政部金融司司长于红回应21世纪经济报道记者提问表示，推动高质量发展，最重要的是加快高水平科 技自立自强，积极发展新质生产力。2025年，按照党中央、国务院决策部署，财政部综合运用了资金支 持、税收优惠、财政金融、政府采购等一系列政策工具，支持科技创新和产业创新融合发展，加 ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Elekta's Evo CT-Linac has received FDA 510(k) clearance, enabling its use in radiation oncology across the U.S. [1][8] - The FDA clearance is a pivotal part of Elekta's strategy to enhance its presence in the U.S. market, promoting personalized and precise radiation therapy [2][4] - The stock price of EKTAY increased by 3.7% following the announcement, with a 38.4% rise over the past six months, outperforming the industry and S&P 500 [3] Company Developments - The Evo CT-Linac's FDA approval allows for commercialization in the U.S., expanding Elekta's market in radiation oncology [4] - The system's advanced imaging and AI capabilities are expected to improve operational efficiency and support revenue growth through increased adoption in clinics [2][4] - Elekta is implementing a new operating model aimed at accelerating product development and enhancing operational efficiency, projected to save at least SEK 500 million annually [13] Product Features - Evo CT-Linac integrates high-quality CT imaging with linear accelerator functionality, enhancing tumor visualization during treatment [1][9] - The Iris imaging technology, which is AI-driven, minimizes scatter and improves image clarity, aiding clinicians in making better treatment decisions [10][11] - The system is designed for easy upgrades to existing Elekta linear accelerators, facilitating adoption and extending system life [10] Market Outlook - The radiation therapy market is projected to reach $8.64 billion by 2026, with a CAGR of 9% through 2035, driven by rising cancer patient numbers and technological advancements [12]

Core Insights - IBA has signed a contract with the University of Texas MD Anderson Cancer Center to modernize its Proton Therapy Center in Houston with three ProteusONE systems, enhancing cancer treatment capabilities [1][2][3] Company Overview - IBA (Ion Beam Applications S.A.) is a leader in particle accelerator technology and proton therapy solutions, employing approximately 2,000 people globally [5] - The company is listed on the EURONEXT stock exchange and is recognized as a certified B Corporation, meeting high social and environmental performance standards [5][6] Contract Details - The project was awarded to IBA through a competitive RFP process, and the typical price for one ProteusONE solution, including maintenance, ranges from USD 45 to 55 million [2][10] - This contract will be recorded in IBA's 2025 order intake, with the first installment triggering the announcement of the commercial contract [10] Technological Impact - The ProteusONE systems are designed to integrate future innovations, supporting improved patient care and advanced research activities [3] - MD Anderson's recent clinical trial results position proton therapy as a new standard of care for advanced oropharyngeal cancer, highlighting the effectiveness of IBA's technology [3][11] Industry Context - MD Anderson Cancer Center is ranked 1 in cancer care by U.S. News & World Report and is a leading institution in cancer research and treatment [1][8] - The collaboration aligns with both organizations' missions to advance cancer treatment and improve patient outcomes [3][6]

转自：嘉兴日报 （来源：嘉兴日报） 秀洲妇保院新院区启用在即，超多亮点抢先解锁！回顾：盼了又盼，嘉兴市秀洲区人民医院高新院区 （嘉兴市秀洲区妇幼保健院）启用进入倒计时啦！医院官方公告明确，1月22日，这座承载着区域妇幼 健康新期待的现代化医疗中心，将以全新姿态正式迎接市民。亮点：医疗设备的全面升级与智慧化建 设，是新院区的核心竞争力。检验科引进贝克曼库尔特全自动检测流水线，凭借"一管血完成多项检 测"的高效优势，每小时可处理样本高达1500管；全自动发药机15秒内即可完成单张处方的精准调配， 日处理处方能力达2000张，彻底让患者告别取药排队的繁琐等待。读友：这样的妇保院令人期待。读 友：秀洲妇保院新院区将开启便捷就医新时代！ ...

Group 1 - The last commentary on FONAR Corporation (FONR) was in September of the previous year, resulting in a downgrade of the company due to shares trading at $15.60, which subsequently fell below $14 [1] - The company specializes in magnetic resonance imaging (MRI) technology [1] Group 2 - The commentary reflects a strategy focused on investing in undervalued profitable stocks with strong balance sheets and minimal debt [1] - The approach includes writing calls against positions to generate additional income and managing risk through position sizing and trailing stop losses [1]

Company Overview - Ingersoll Rand is a global company with a revenue of $7.5 billion, an EBITDA margin of 27%, and a free cash flow margin of approximately 17% [4] - The company's market capitalization is $34 billion [4] - Since its IPO of Gardner Denver in 2017 and the acquisition of Ingersoll Rand in 2020, the total shareholder return has exceeded 330% [4] Life Science Technologies Platform - The presentation at the JPMorgan Healthcare Conference marks the first time Ingersoll Rand is presenting at this prestigious event [2] - The CEO, Vicente Reynal, emphasized the importance of the Life Science platform, which will be further detailed by Scott Watson, SVP and General Manager [2]

Core Viewpoint - Avanos Medical aims to enhance patient quality of life through a focused long-term strategy that emphasizes durable growth and value creation [2]. Group 1: Company Strategy - The company is experiencing solid mid-single-digit growth and holds market-leading positions with established reimbursement [4]. - Avanos is expanding its global direct sales organization and has a newly appointed management team, which includes several new leaders [4]. - The company has an attractive M&A pipeline that presents growth opportunities and maintains a strong balance sheet to support capital deployment [4].

Core Insights - Thermo Fisher Scientific's pharmaceutical services business has secured multiple contracts aimed at assisting clients in relocating production from Europe or Asia to the U.S. [1] Company Summary - The CEO of Thermo Fisher Scientific, Marc, highlighted the company's strategic focus on expanding its pharmaceutical services to support clients in shifting their manufacturing operations to the U.S. [1]

Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services. ...